A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2017.05.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase I/Ii Study of Carfilzomib, Bendamustine, and Dexamethasone (CBD) in Patients With Newly Diagnosed Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2020English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Response-Adapted Intensification With Cyclophosphamide, Bortezomib, and Dexamethasone Versus No Intensification in Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial

The Lancet Haematology
Hematology
2019English

Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design

Future Oncology
MedicineCancer ResearchOncology
2020English

Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Cancer Science
Cancer ResearchMedicineOncology
2019English

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03)

Clinical Cancer Research
Cancer ResearchOncology
2019English

The MUK Five Protocol: A Phase II Randomised, Controlled, Parallel Group, Multi-Centre Trial of Carfilzomib, Cyclophosphamide and Dexamethasone (CCD) vs. Cyclophosphamide, Bortezomib (Velcade) and Dexamethasone (CVD) for First Relapse and Primary Refractory Multiple Myeloma

BMC Hematology
HematologyMolecular Biology
2016English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial

The Lancet Oncology
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy